Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Core Insights - Terns Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing high-impact medicines, with its lead program TERN-701 being a selective BCR-ABL inhibitor aimed at improving treatment for chronic myeloid leukemia (CML) [3] Upcoming Investor Conferences - Terns Pharmaceuticals will participate in several investor conferences in March 2026, including: - TD Cowen's 46th Annual Health Care Conference on March 2, 2026, at 3:50 p.m. ET in Boston, MA [2] - Leerink Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET in Miami, FL [2] - Barclays 28th Annual Global Healthcare Conference on March 10, 2026, in Miami, FL [2] - The Citizens Life Sciences Conference on March 11, 2026, at 9:00 a.m. ET in Miami, FL [2] - Live webcasts of the fireside chats will be available on Terns' investor relations page, with replays archived for at least 30 days [2]